Insulin resistance prediction from wearables and routine blood biomarkers

In an era defined by unprecedented technological advancement, the convergence of artificial intelligence (AI), ubiquitous wearable technology, and traditional medical diagnostics is heralding a new dawn in preventative healthcare. One of the most critical frontiers in this revolution is the early prediction of insulin resistance – a silent, often undiagnosed precursor to a cascade of severe health complications, most notably Type 2 Diabetes (T2D), but also cardiovascular disease, certain cancers, and neurodegenerative disorders. The sheer scale of the challenge is staggering: globally, T2D affects hundreds of millions, with projections indicating a continued exponential rise. A significant portion of these individuals remain unaware of their precarious metabolic state until the condition has progressed to a point where intervention becomes more challenging and less effective. Traditional diagnostic methods, while foundational, often rely on infrequent, point-in-time measurements like fasting glucose, HbA1c, and insulin levels, which may not capture the dynamic, often subtle shifts indicative of developing insulin resistance. These methods typically provide a snapshot rather than a continuous narrative, meaning early, actionable insights are frequently missed.

However, the landscape is rapidly transforming. The proliferation of smart wearables – from watches and rings to continuous glucose monitors (CGMs) – has democratized the collection of physiological data, transforming individuals into walking data streams. These devices capture a wealth of real-time information: heart rate variability (HRV), sleep quality, physical activity levels, skin temperature, and even blood oxygen saturation. When this rich, continuous dataset is fused with insights gleaned from